ストックスクリーナーアプリを入手
16.26
2.85%
0.45
プレマーケット:
16.24
-0.02
-0.12%
前日終値:
$15.81
開ける：
$15.88
24時間の取引高:
649.18K
Relative Volume:
0.49
時価総額：
$1.67B
収益：
$83.98M
当期純損益:
$-264.46M
株価収益率:
-5.345
EPS:
-3.0421
ネットキャッシュフロー:
$-263.47M
1週間 パフォーマンス:
+2.98%
1か月 パフォーマンス:
-1.75%
6か月 パフォーマンス:
+78.29%
1年 パフォーマンス:
+14.03%
1日の値動き範囲:
$15.46
$16.45
1週間の範囲:
$15.09
$16.45
52週間の値動き範囲:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
名前
Nurix Therapeutics Inc
セクター
電話
(415) 660-5320
住所
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
16.26 | 1.63B | 83.98M | -264.46M | -263.47M | -3.0421 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-03-17 | 開始されました | Leerink Partners | Market Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-11 | 開始されました | Jefferies | Buy |
| 2024-09-06 | 再開されました | Robert W. Baird | Outperform |
| 2024-07-31 | 開始されました | Truist | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-09 | 開始されました | Barclays | Overweight |
| 2023-02-28 | 開始されました | Oppenheimer | Outperform |
| 2022-10-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-12-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-30 | 再開されました | Piper Sandler | Overweight |
| 2021-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-11-19 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | Stifel | Buy |
すべてを表示
Nurix Therapeutics Inc (NRIX) 最新ニュース
ARK Investment Management LLC Has $13.96 Million Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. $NRIX Stock Position Increased by Amova Asset Management Americas Inc. - MarketBeat
Handelsbanken Fonder AB Buys 240,000 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Planned stock sale by Nurix (NRIX) chief legal officer disclosed - Stock Titan
Christine Ring sells RSU shares (NRIX) under 10b5-1 plan via Morgan Stanley - Stock Titan
Growth Review: Does Nurix Therapeutics Inc have a sustainable dividendForecast Cut & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Nurix Therapeutics (NRIX) Valuation Check After Recent Share Price Volatility And Rich Price To Sales Multiple - Yahoo Finance
Nurix Therapeutics, Inc. (NRIX): Biotechnology Innovator With 86% Potential Upside - DirectorsTalk Interviews
NRIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Avoiding Lag: Real-Time Signals in (NRIX) Movement - Stock Traders Daily
NRIX PE Ratio & Valuation, Is NRIX Overvalued - Intellectia AI
Redmile Group Increases Nurix Therapeutics Stake by 4.4M Shares - Intellectia AI
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - Yahoo Finance
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - The Motley Fool
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Is There a 90% Upside Potential on the Horizon? - DirectorsTalk Interviews
Baker Bros discloses 7.2% Nurix (NRIX) ownership stake - Stock Titan
NRIX Technical Analysis & ETF Price Forecast - Intellectia AI
Discipline and Rules-Based Execution in NRIX Response - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight - MarketBeat
Does Nurix Therapeutics Inc. have a sustainable dividendJuly 2025 Institutional & Entry Point Confirmation Signals - mfd.ru
Is Nurix Therapeutics Inc. undervalued by DCF analysisQuarterly Portfolio Report & Accurate Entry/Exit Alerts - mfd.ru
What is the long term forecast for Nurix Therapeutics Inc. stockEarnings Summary Report & Reliable Trade Execution Plans - mfd.ru
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Emerging Potential With 90% Upside - DirectorsTalk Interviews
NRIX: Degrader therapies advance in immunology, with key milestones expected for STAT6 and BTK programs - TradingView
Why Nurix Therapeutics Inc. stock remains resilient2025 Earnings Impact & Daily Technical Stock Forecast Reports - mfd.ru
Nurix (NASDAQ: NRIX) CFO awarded 93,750 options and 42,875 RSUs - Stock Titan
Ring Christine, chief legal officer at Nurix, sells $237k in NRIX stock - Investing.com Canada
Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration - Sahm
HC Wainwright remains a buy on Nurix Therapeutics (NRIX) - MSN
Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss - Sahm
VIX Spike: Can Nurix Therapeutics Inc sustain its profitabilityGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share ShelfWhat's Changed - Yahoo Finance
Stifel raised Nurix Therapeutics, Inc. (NRIX) price target to $35 and maintains buy ahead of 2026 catalysts - MSN
Nurix Therapeutics advances study for NX-5948 in CLL and SLL patients - MSN
Behavioral Patterns of NRIX and Institutional Flows - Stock Traders Daily
Is Nurix Therapeutics Inc forming a bullish divergenceWeekly Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory - Finviz
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts - Finviz
Research Analysts Offer Predictions for NRIX Q1 Earnings - MarketBeat
Published on: 2026-02-01 10:49:34 - baoquankhu1.vn
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts - 富途牛牛
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Unpacking A 70% Upside Potential - DirectorsTalk Interviews
Nurix Therapeutics chief legal officer Ring sells $73k in stock - Investing.com India
Nurix Therapeutics chief legal officer Ring sells $73k in stock By Investing.com - Investing.com Nigeria
Houte Hans Van Sells 3,661 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,895 Shares - MarketBeat
H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX) - Finviz
Nurix Therapeutics CSO Gwenn Hansen sells $81k in shares By Investing.com - Investing.com Canada
Nurix Therapeutics CFO Hans van Houte sells $61k in shares - Investing.com Canada
Nurix Therapeutics Inc (NRIX) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):